Investigator Perspectives

Steven Sherman, MD, FACE, provides insight on the treatment of radioactive iodine-refractory differentiated thyroid cancer and the management of adverse events.

Implications for assessing MRD status in patients with transplant-ineligible myeloma and treating appropriate patients with the combination of daratumumab, lenalidomide, and dexamethasone.

Recent updates from the ASH 2020 annual meeting on the phase 1b/2 CARTITUDE-1 trial for relapsed/refractory multiple myeloma.

Data are reviewed from the phase 3 IMbrave150 trial for unresectable hepatocellular carcinoma.

The most interesting developments and approvals in breast cancer treatment in the last year and expectations regarding data that will be presented on at the upcoming 2020 San Antonio Breast Cancer Symposium.

Dr David Spigel provides information on the PACIFIC trial, including the 4-year update.

A key opinion leader provides insight into recent data updates from ongoing trials studying the management of GvHD with promising regimens. 

A key opinion leader provides an overview of emerging data for a promising CD-19 targeted therapy and discusses how it has impacted the treatment paradigm.

Michael Wang, MD, reacts to recent data and the potential to treat patients with relapsed or refractory mantle cell lymphoma with KTE-X19, an investigational CAR T-cell therapy.

A key opinion leader discusses how the role tucatinib is evolving in the management of HER2-positive metastatic breast cancer.

A key opinion leader discusses the evolving treatment landscape for radioiodine refractory differentiated thyroid carcinoma, with special consideration of the phase 3 SELECT trial.

Saeed Sadeghi, MD, comments on the utilization of FGFR2 inhibitors as treatment for advanced cholangiocarcinoma.

A primary researcher on the Phase III ADAURA trial provides an overview of the ground-breaking data for managing patients with EGFR-positive NSCLC (non–small cell lung cancer).

A discussion on the development of targeted therapies for the management of advanced cholangiocarcinoma, with consideration of multiple ongoing trials with notable outcomes.

How the recent FDA approval of the subcutaneous formulation of daratumumab in multiple myeloma will affect patients and oncologists from practical and clinical standpoints.

Sara M. Tolaney, MD, MPH, discusses newer approaches to managing early stages of HER2+ breast cancer in both the neoadjuvant and adjuvant spaces.

Follicular Lymphoma

Lung Cancer

Colorectal Cancer

Chronic Lymphocytic Leukemia

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Breast Cancer

Chronic Lymphocytic Leukemia

Graft versus Host Disease

Ovarian Cancer

Non-Hodgkin Lymphoma

Prostate Cancer